Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.40 |
| ▸ | FURIN | P09958 | 4/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24224636 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL22138625 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL23943282 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL27197502 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL16946352 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL24476142 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL22128021 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL22128022 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL32667737 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL21570028 | 0.94 | FAP (0.39) | FAPFURINMAP1LC3BHTTNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727586-A1 | ANTI-CD5 ANTIBODIES AND THEIR USES | Synthis Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260053939-A1 | Combination Therapy for Cancer | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-02-26 | — | — | US | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024258967-A1 | ANTI-CD5 ANTIBODIES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4469484-A1 | COMBINATION THERAPY FOR CANCER | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024182569-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-09-06 | — | — | WO | disclosed |
| CN-118591560-A | Combination therapy for cancer | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023159176-A1 | COMBINATION THERAPY FOR B-CELL DISORDERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023144702-A1 | COMBINATION THERAPY FOR CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-03 | — | — | WO | disclosed |
| US-20230144203-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | SYNTHIS THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | US | disclosed |
| EP-4088739-A1 | METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATE | Eisai R&D Management Co., Ltd. (JP) | 2022-11-16 | — | — | EP | disclosed |
| CN-115052663-A | ALK5 inhibitor conjugates and uses thereof | 辛瑟斯治疗股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3986468-A1 | ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | Synthis Therapeutics, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114269388-A | antibody-ALK 5 inhibitor conjugates and uses thereof | 辛瑟斯治疗股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053939-A1 | Combination Therapy for Cancer | BCL6, PSMB6, PDCD6 | FAP 2223/4885FURIN 4825/4885MAP1LC3B 439/4885 |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | FAP 69/4885FURIN 3714/4885MAP1LC3B 1656/4885 |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | ALK, ALKBH5, ALKBH3 | FAP 5/4885FURIN 3806/4885MAP1LC3B 1573/4885 |
| US-20230144203-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | ERLIN1, ERLIN2, EZR | FAP 2908/4885FURIN 274/4885MAP1LC3B 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.